Intercure Ltd.INCREarnings & Financial Report
Nasdaq · Health Care · Pharmaceutical Preparations
Intercure Ltd. is a biopharmaceutical company that develops, manufactures and sells prescription and over-the-counter therapeutic products for chronic respiratory, cardiovascular and metabolic conditions. Its core markets are North America, the EU and Israel, serving consumer healthcare and prescription patient segments.
INCR Q2 FY2025 Key Financial Metrics
Revenue
$35.1M
Gross Profit
$10.3M
Operating Profit
$1.5M
Net Profit
N/A
Gross Margin
29.4%
Operating Margin
4.4%
Net Margin
N/A
YoY Growth
N/A
Intercure Ltd. Q2 FY2025 Financial Summary
Intercure Ltd. reported revenue of $35.1M for Q2 FY2025, with a net profit of N/A (N/A margin). Cost of goods sold was $24.8M, operating expenses totaled $8.8M.
Key Financial Metrics
| Total Revenue | $35.1M |
|---|---|
| Net Profit | N/A |
| Gross Margin | 29.4% |
| Operating Margin | 4.4% |
| Report Period | Q2 FY2025 |
Income Statement
| Q2 2025 | |
|---|---|
| Revenue | $35.1M |
| YoY Growth | N/A |
Balance Sheet
| Q2 2025 | |
|---|---|
| Assets | N/A |
| Liabilities | N/A |
| Equity | N/A |
Cash Flow
No data available for this period